http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
BioLife Solutions Announces First Quarter 2018 Financial Results
-
BioLife Solutions to Report First Quarter 2018 Financial Results and Provide Business Update on May 10, 2018
-
BioLife Solutions Receives $2.6 Million from Exercise of Warrants
-
Casdin Capital to Become Shareholder in BioLife Solutions
-
BioLife Solutions (BLFS) Announces Prelim. Q1 Revenue of $3.8 Million
-
BioLife Solutions Announces Preliminary First Quarter 2018 Revenue of $3.8 Million, up 61% Year-over-Year and 22% Sequentially
-
BioLife Solutions (BLFS) and SAVSU Technologies Secure 2nd Patent for Next Generation Cold Chain Technologies Designed for Cell & Gene Therapies
-
BioLife Solutions and SAVSU Technologies to be Awarded Second Patent for Next Generation Cold Chain Technologies Designed for Cell and Gene Therapies
-
BioLife Solutions CryoStor® Cell Freeze Media Highlighted in Mayo Clinic/MD Anderson Journal Article on Preservation of Patient-Derived Xenografts for Cancer Research
-
BioLife Solutions Announces Fourth Quarter and Full Year 2017 Financial Results
-
BioLife Solutions to Report Fourth Quarter and Full Year 2017 Financial Results and Provide Business Update on March 8, 2018
-
BioLife Solutions Executes OEM Agreement with MilliporeSigma
-
BioLife Solutions Announces SAVSU Alliance with World Courier
-
SAVSU Technologies and BioLife Solutions Increase evo® Intellectual Property Estate with Notice of Allowance of New Patent for Cold Chain Technologies
-
BioLife Solutions to Attend and Present at Upcoming Investor & Scientific Conferences
-
BioLife Solutions (BLFS) Reports Preliminary 2017 Revenue Increase of 34% to $11M
-
BioLife Solutions Announces Preliminary 2017 Revenue Increase of 34% to $11 Million
-
BioLife Solutions Executes Supply Agreement with Iovance Biotherapeutics
-
BioLife Solutions Executes Additional Long-Term Supply Agreement with Leading T Cell Therapy Customer
-
BioLife Solutions Announces Third Quarter 2017 Financial Results
-
BioLife Solutions to Report Third Quarter 2017 Financial Results and Provide Business Update on November 9, 2017
-
BioLife Solutions and SAVSU Providing Enhanced Cold Chain Technologies for 8 UCSF Clinical Trials of Treg Cell Therapies
-
BioLife Solutions Receives $1.9 Million from Exercise of Warrants
-
BioLife Solutions (BLFS) Customer Kite Pharma Granted FDA Approval for Yescarta (Axicabtagene Ciloleucel) CAR T-Cell Therapy
-
BioLife Solutions Customer Kite Pharma Receives FDA Approval for Yescarta™ (Axicabtagene Ciloleucel) CAR T-Cell Therapy
-
BioLife Solutions to Present at Upcoming Investor Conferences
-
BioLife Solutions CryoStor® Cell Freeze Media Embedded in Cellular Biomedicine Group Clinical Trial of AlloJoin™
-
BioLife Solutions to Present at September Investment Conferences
-
BioLife Solutions Announces Second Quarter 2017 Financial Results
-
BioLife Solutions to Report Second Quarter 2017 Financial Results and Provide Business Update on August 10, 2017
-
BioLife Solutions (BLFS) Reports Supply Agreement with Celyad for CryoStor
-
BioLife Solutions Executes Supply Agreement with Celyad for CryoStor® Use in Natural Killer Receptor based T-Cell (NKR-T) Platform Targeting Solid Tumors and Blood Cancers
-
BioLife Solutions CryoStor® Cell Freeze Media Embedded in Invossa™: First Approved Cell and Gene Therapy for Osteoarthritis
-
BioLife Solutions Modifies Existing Credit Facility
-
BioLife Solutions Executes Supply Agreement with Adaptimmune for CryoStor® Use in SPEAR T-Cell Platform
-
BioLife Solutions Announces Q1 2017 Financial Results
-
BioLife Solutions to Report First Quarter 2017 Financial Results and Provide Business Update on May 11, 2017
-
BioLife Solutions Reports 4th Quarter and Full Year 2016 Results
-
BioLife Solutions to Report Fourth Quarter and Full Year 2016 Financial Results and Provide Business Update on March 9, 2017
-
BioLife Solutions Announces 2016 Revenue Growth of 28%
-
BioLife Solutions Amends Existing Credit Facility
-
BioLife Solutions (BLFS) Announces Restructuring of Biologistex Joint Venture
-
BioLife Solutions Restructures biologistex™ Joint Venture
-
BioLife Solutions Executes 10 Year Supply Agreement with TissueGene for CryoStor® Use in Invossa™ Osteoarthritis Cell-Mediated Gene Therapy
-
BioLife Solutions Reports Record Results for Third Quarter 2016
-
BioLife Solutions to Report Third Quarter 2016 Financial Results and Provide Business Update on November 10, 2016
-
BioLife Solutions (BLFS), Brooks Automation Ciollaborate
-
BioLife Solutions and Brooks Life Sciences Partner on Study of Best Practices for Shipping and Storing Time and Temperature Sensitive Biologic Materials
-
BioLife Solutions' CryoStor® Embedded in Manufacturing Process for Promethera Biosciences HepaStem Cell-Based Treatment for Liver Disorders
-
BioLife Solutions (BLFS) Says CryoStor Freeze Media Integrated in Invossa Manufacturing Process

